This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
January 2021
Presentations
Tucatinib | Colorectal Cancer | TPS153
MOUNTAINEER TIP: Open-Label, Phase 2 Study of Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic Colorectal Cancer (Trial in Progress)
SEA-CD40 | Pancreatic Ductal Adenocarcinoma | TPS451
SGNS40-001 TIP: Phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (Trial in Progress)
.png)
Tucatinib | Urothelial Carcinoma | Abstract TPS499
MOUNTAINEER-02 TIP: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress
Ladiratuzumab vedotin | Prostate Cancer | Abstract TPS185
SGNLVA-005 TIP: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (SGNLVA-005, Trial in Progress)